An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708, Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment.

Trial Profile

An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708, Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 25 Jun 2017 Results assessing long-term efficacy and safety data in patients who did not withdraw from the study (n=40), presented at the 22nd Congress of the European Haematology Association
    • 23 Jun 2017 According to a Takeda media release, Paul Richardson is a lead investigator in this trial.
    • 23 Jun 2017 According to a Takeda media release, data from this trial will be presented at the 2017 European Hematology Association (EHA) annual meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top